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Introduction
Zika virus (ZIKV) was first isolated in 1947 (1) and remained relatively neglected by the public health sys-
tem for more than 50 years until its sudden reemergence in the Micronesian island of  Yap in 2007 (2, 3). 
From there, the ZIKV epidemic continued to spread in several Pacific islands, finally reaching the Americas 
in 2015 (4–8). As of  December 2016, 75 countries are experiencing ongoing transmission of  ZIKV (9). 
While the symptoms of  ZIKV infection are typically mild, there is now strong evidence linking ZIKV with 
Guillain-Barré syndrome (GBS) and congenital Zika syndrome (10–16). Thus, it continues to be a public 
health concern with severe social and economic impact. With no specific and licensed treatment available 
for ZIKV, there remains an urgent need to develop ZIKV prophylactic and therapeutic agents.
ZIKV is a flavivirus that is transmitted by Aedes mosquitoes. Typical symptoms include fever, 
arthritis/arthralgia, skin rash, conjunctivitis, joint pain, and headache (3, 17). Since the mode of  trans-
mission of  ZIKV and the clinical symptoms caused by ZIKV infection are highly similar to that of  
dengue virus (DENV), distinguishing the 2 related flaviviruses in a clinical setting where both viruses 
are cocirculating can be challenging (18, 19). Conversely, the close antigenic relationship between 
ZIKV and DENV imply the existence of  cross-reactive antibodies that are able to confer cross-protec-
tion against both viruses (20–24).
Zika virus (ZIKV) infections have been linked with neurological complications and congenital Zika 
syndrome. Given the high level of homology between ZIKV and the related flavivirus dengue virus 
(DENV), we investigated the level of cross-reactivity with ZIKV using a panel of DENV human 
mAbs. A majority of the mAbs showed binding to ZIKV virions, with several exhibiting neutralizing 
capacities against ZIKV in vitro. Three of the best ZIKV-neutralizing mAbs were found to recognize 
diverse epitopes on the envelope (E) glycoprotein: the highly conserved fusion-loop peptide, a 
conformation-specific epitope on the E monomer, and a quaternary epitope on the virion surface. 
The most potent ZIKV-neutralizing mAb (SIgN-3C) was assessed in 2 type I interferon receptor–
deficient (IFNAR–/–) mouse models of ZIKV infection. Treatment of adult nonpregnant mice with 
SIgN-3C rescued mice from virus-induced weight loss and mortality. The SIgN-3C variant with Leu-
to-Ala mutations in the Fc region (SIgN-3C-LALA) did not induce antibody-dependent enhancement 
(ADE) in vitro but provided similar levels of protection in vivo. In pregnant ZIKV-infected IFNAR–/– 
mice, treatment with SIgN-3C or SIgN-3C-LALA significantly reduced viral load in the fetal organs 
and placenta and abrogated virus-induced fetal growth retardation. Therefore, SIgN-3C-LALA holds 
promise as a ZIKV prophylactic and therapeutic agent.
2insight.jci.org   https://doi.org/10.1172/jci.insight.92428
R E S E A R C H  A R T I C L E
In order to characterize the cross-reactivity of  human DENV mAbs against ZIKV, a validated panel 
of  DENV-specific mAbs cloned from dengue patient plasmablasts was investigated (25, 26). We found 3 
cross-reactive mAbs with the capacity to inhibit ZIKV infection in vitro that recognize different epitopes 
within the various ZIKV antigens. SIgN-3C, the mAb with the highest neutralizing capacity, was then 
assessed in both nonpregnant and pregnant murine models of  ZIKV infection. Our results further strength-
en the importance of  antibody-mediated therapy in combating ZIKV.
Results
Broad ZIKV cross-reactivity by human DENV mAbs. Twenty-three human DENV mAbs that were cloned from 
the plasmablasts of  2 DENV-infected patients (25, 26) were assessed for cross-reactivity against ZIKV using 
virion-based ELISA assays. All but 2 of  these human mAbs could recognize ZIKV whole virions at the con-
centration of  1 μg/ml (Figure 1A). This indicates a high level of  cross-reactivity to ZIKV, consistent with the 
presence of  structural similarities in the immunodominant regions between ZIKV and DENV (20, 21, 23).
Some human DENV mAbs neutralize ZIKV. The 23 human DENV mAbs were assessed for their ability to 
inhibit ZIKV infection of  Vero-E6 cells (Supplemental Table 1; supplemental material available online with 
this article; https://doi.org/10.1172/jci.insight.92428DS1). While most of  the antibodies were non-neu-
tralizing at the concentrations tested, human mAbs 1B-H1L1, 2F-H1L3, and SIgN-3C showed considerable 
capacity to neutralize ZIKV in vitro (Figure 1, B–D). Based on the estimated antibody dose required for 50% 
neutralization (IC50), SIgN-3C demonstrated higher neutralizing activity (IC50 = 0.93 μg/ml) against ZIKV 
than 1B-H1L1 (IC50 = 19.25 μg/ml) and 2F-H1L3 (IC50 > 30 μg/ml). Furthermore, only SIgN-3C was 
able to approach complete neutralization at saturating concentrations, whereas the inhibition by 1B-H1L1 
and 2F-H1L3 was incomplete (Figure 1, B–D), even though SIgN-3C demonstrated lower binding affin-
ity for immobilized ZIKV virions than 1B-H1L1 and 2F-H1L3 (Figure 1E). The concentrations required 
for half-maximal binding to ZIKV virions were 0.011 μg/ml, 0.051 μg/ml, and 0.30 μg/ml for 1B-H1L1, 
2F-H1L3, and SIgN-3C, respectively. Importantly, these 3 selected mAbs also showed binding and neutraliz-
ing activity against the Brazilian ZIKV PE243 strain (Supplemental Figure 1). Therefore, these human mAbs 
may be binding to different ZIKV epitopes that differ in accessibility or in their roles during infection.
ZIKV antigens recognized by mAbs. DENV envelope (E) glycoprotein, pre-membrane (prM) protein, and 
non-structural protein 1 (NS1) are the major antigenic targets in DENV infection (27, 28). To identify the ZIKV 
antigens recognized by the 3 human DENV mAbs with significant ZIKV neutralizing capacity, we created a 
panel of K562 cell lines transduced to express the ectodomain of ZIKV E, full-length ZIKV prM, and full-length 
ZIKV NS1 on the cell surface, fused to the transmembrane anchor of platelet-derived growth factor receptor. 
Cell surface display of the respective ZIKV antigens was confirmed by antibody labeling of epitope tags (Sup-
plemental Figure 2). Each transduced cell line and control untransduced K562 cells were incubated with 1 μg/
ml 1B-H1L1, 2F-H1L3, or SIgN-3C prior to detection with a fluorescent secondary antibody. K562 cells surface 
expressing ZIKV E were clearly bound by 1B-H1L1 and 2F-H1L3 (Supplemental Figure 3A), proving that these 
2 antibodies recognize folded E glycoprotein. As expected, 1B-H1L1 and 2F-H1L3 also did not bind to cells sur-
face-displaying ZIKV prM or NS1 (Supplemental Figure 3B). SIgN-3C at 1 μg/ml did not recognize any of the 
transduced cell lines, while at 10 μg/ml, there was a very low level of binding to cells surface-displaying ZIKV 
E (Supplemental Figure 3). Given that SIgN-3C bound well to whole ZIKV virions at 1 μg/ml (Figure 1E), we 
propose that this mAb recognizes a quaternary epitope on the virion surface, such as the interface of the E dimer, 
which has been described to be the epitope of a class of neutralizing human DENV mAbs (20).
Epitope mapping and localization. To identify any specific peptide regions responsible for antibody 
recognition, 2 overlapping peptide libraries of  DENV and ZIKV E glycoproteins were synthesized. 
The 18-mer overlapping peptides (with an offset of  8 amino acids) were designed using the DENV3 
consensus sequence and ZIKV Polynesian isolate sequence (Supplemental Figure 4). Peptide-based 
ELISA was first performed using pools of  up to 5 consecutive peptides from each library (Supplemen-
tal Figure 5). 1B-H1L1 bound to several peptide pools from both DENV and ZIKV, whereas 2F-H1L3 
gave low signals for all pools. Since 2F-H1L3 bound strongly to cells surface-displaying ZIKV E ecto-
domain (Supplemental Figure 3), the results suggest that this mAb recognizes a nonlinear conforma-
tional epitope on ZIKV E. Corroborating this hypothesis, an immunoblotting experiment on the lysate 
of  cells expressing ZIKV E showed that 2F-H1L3 could not recognize the denatured E glycoprotein. 
SIgN-3C did not bind to any DENV or ZIKV linear peptides, which coincides with the hypothesis that 
this mAb is targeting a quaternary epitope on the DENV/ZIKV virion surface (20).
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A second ELISA experiment was performed to test binding of  1B-H1L1 to the individual peptides 
from the positive pools (Supplemental Figure 6). 1B-H1L1 strongly recognized peptides from the fusion-
loop regions of  both DENV (Supplemental Figure 6A) and ZIKV (Supplemental Figure 6B), which are 
highly conserved (Supplemental Figure 6C). Identified epitope sequences were mapped onto available 3D 
crystal structures of  the DENV E (Protein Data Bank [PDB] identifier 3J6U) and ZIKV E glycoprotein 
(PDB identifier 5IZ7) (29, 30) (Supplemental Figure 7). Spatial positioning on the dimeric E glycoprotein 
shows that the identified epitopes are located on exposed surface regions on the distal face of  the E protein, 
accessible to antibody binding in the fully assembled viral particle.
SIgN-3C mediates antibody-dependent infection enhancement. Antibody-dependent infection enhancement 
(ADE) is a phenomenon that has been extensively studied in DENV infection in vitro and in vivo (31–35). To 
assess if  ADE can occur during ZIKV infection, low to very low concentrations (30 μg/ml to 0.03 ng/ml) of  
1B-H1L1, 2F-H1L3, and SIgN-3C mAb were tested using the ZIKV-ADE assay. A clear ADE phenomenon was 
observed, with a maximum fold increase in ZIKV viral load observed in the presence of 0.3 μg/ml of SIgN-3C 
(Figure 2A). The effect of ZIKV-ADE infection declined when lower SIgN-3C concentrations were used in the 
Figure 1. Binding and neutralizing activity of human DENV mAbs against Zika virus. (A) Level of recognition of Zika virus (ZIKV) whole virions by human 
dengue virus (DENV) mAbs was tested at 1 μg/ml (n = 3) and determined by ELISA using purified ZIKV virions. Data are presented as mean ± SD. (B–D) 
Neutralizing capacities of selected human DENV mAbs against ZIKV in vitro. ZIKV was preincubated with serial dilutions of human DENV mAbs 1B-H1L1 
(B), 2F-H1L3 (C), or SIgN-3C (D) prior to infecting Vero-E6 cells at MOI of 10. Mock-infected and virus-only conditions were used as controls. Infectivity 
was quantified 48 hours after infection by immunofluorescence. Data are presented as mean ± SEM of 3 to 4 independent experiments, normalized to 
virus-only control. Nonlinear regression fitting was used to determine the IC50 values. (E) Binding curves of selected mAbs by ZIKV virion ELISA. OD values 
were normalized to the result at 30 μg/ml mAb.
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preincubation steps. To resolve the safety concern of using SIgN-
3C as therapeutic antibody against ZIKV, the Fc mutant version of  
the 3C antibody (SIgN-3C-LALA) was generated by introducing 
Leu-to-Ala mutations in the Fc region that disrupt binding to Fc 
receptors (26, 36). SIgN-3C-LALA demonstrated similar ZIKV 
binding (Figure 2B) and neutralizing activity (Figure 2C), without 
enhancing ZIKV infection in vitro (Figure 2A).
Therapeutic potential of  SIgN-3C and SIgN-3C-LALA mAbs 
against ZIKV-induced mortality in nonpregnant IFNAR–/– mice. To 
assess the therapeutic potential of SIgN-3C and SIgN-3C-LALA, 
we employed an established mouse model using mice deficient for 
the type I interferon receptor (IFNAR–/–) (37). IFNAR–/– mice were 
infected subcutaneously (s.c.) with ZIKV, and SIgN-3C, SIgN-
3C-LALA, or isotype control were administered intraperitoneally 
(i.p.) at 1, 4, and 8 days postinfection (dpi). Virus-infected mice 
injected with the isotype control showed symptoms of weakness 
with rapid weight loss from 4 dpi onwards and all died on 7 to 
8 dpi (Figure 3, A and B). In contrast, virus-infected mice treated with either SIgN-3C or the LALA variant 
did not display any signs of illness and continued to gain weight until they were euthanized at 4 weeks after 
treatment (Figure 3, A and B). Survival of these animals was due to the control of virus replication in both the 
circulatory system and the major organs (Figure 3, C and D). Both treatments suppressed peak viremia from 3 
to 7 dpi by 3 to 4 orders of magnitude, and cleared viremia by 12 dpi (Figure 3C). Importantly, at 6 dpi when 
control mice displayed severe ZIKV-induced symptoms prior to mortality at 7 dpi, viral loads in the brain, liver, 
kidney, testes, and popliteal lymph nodes (pLNs) were significantly reduced in mAb-treated mice (Figure 3D). 
These data suggest that treatment with SIgN-3C or its LALA variant prevented ZIKV-induced mortality in 
IFNAR–/– animals with a comparable degree of protective efficacy.
SIgN-3C and SIgN-3C-LALA protect fetuses from ZIKV-induced growth retardation in pregnant IFNAR–/– mice. 
ZIKV infection of  pregnant mice deficient in type I interferon signaling has recently been reported to result in 
fetal growth restriction (38, 39). We next explored the potential of  SIgN-3C and SIgN-3C-LALA to protect 
IFNAR–/– fetuses from ZIKV-induced congenital pathology. Pregnant IFNAR–/– mice infected with a high 
virus titer (107 PFU) at E10.5 resulted in growth retardation in the fetuses with high levels of  viral RNA 
(vRNA) detected in the amniotic fluid, placenta, and fetal brain at E16.5 (Figure 4). vRNA was detectable 
in the fetal liver at E16.5 at a much lower titer (Figure 4D). Notably, fetuses from virus-infected and iso-
type-treated mice were smaller in size and had lower whole-body and head mass compared with fetuses from 
mock-infected mice at E16.5 (Figure 4, A and B). However, administration of  SIgN-3C or SIgN-3C-LALA at 
0, 1, and 3 dpi restored head and whole-body mass of  fetuses from virus-infected animals to values similar to 
those from noninfected mice (Figure 4, A and B). Protection from ZIKV-induced congenital developmental 
deficiency was also associated with lower viral loads in the amniotic fluid (Figure 4C), placenta, fetal brain, 
and fetal liver in the treated mice (Figure 4D). Both the fetal weight and viral load in the various organs tested 
were similar between SIgN-3C–treated and SIgN-3C-LALA–treated mice (Figure 4).
Figure 2. Modified SIgN-3C antibody (SIgN-3C-LALA) abrogated ADE 
in in vitro ZIKV infection. (A) Antibody-dependent enhancement 
(ADE) of Zika virus (ZIKV) infection. ZIKV was preincubated with serial 
dilutions of 1B-H1L1, 2F-H1L3, SIgN-3C, and SIgN-3C-LALA (0.03 ng/ml 
to 30 μg/ml) before infecting K562 cells at MOI of 10. Noninfected cells 
and virus infection in the absence of mAb (control infection, gray dot-
ted line) were used as controls. Results are presented as mean ± SEM 
of virus titer fold increase with the presence of different concentra-
tions of mAbs, relative to control infection. Results are presented as 
average of 2 independent experiments. (B) Binding curves of SIgN-3C 
and SIgN03C-LALA mAbs by ZIKV virion ELISA. OD values were nor-
malized to the result at 3 μg/ml. (C) SIgN-3C-LALA antibody preserves 
good neutralizing activity against ZIKV. Data are presented as mean ± 
SEM of 4 independent experiments, normalized to virus-only control. 
Nonlinear regression fitting was used to determine the IC50 values.
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Discussion
Given the greater than 50% protein sequence identity between DENV and ZIKV, it is not surprising that 
almost all of  the human DENV mAbs studied had some level of  cross-reactivity with ZIKV. While we 
were concluding this work, other groups also reported a high level of  ZIKV cross-reactivity by DENV 
antibodies or sera from DENV patients (20–23). Here, we identified and characterized 3 DENV mAbs 
with neutralizing activity against ZIKV, with 3 different modes of  binding to ZIKV E glycoprotein. 
1B-H1L1 recognizes a linear epitope, the conserved fusion-loop region of  DENV and ZIKV. 2F-H1L3 
recognizes a nonlinear conformational epitope present on the folded E glycoprotein monomer, which 
we expressed on the K562 cell surface. Despite binding to whole ZIKV virions, SIgN-3C had very weak 
binding to E glycoprotein monomer. Barba-Spaeth et al. categorized their DENV/ZIKV cross-reactive 
antibodies into those targeting the fusion-loop epitope and those targeting the E-dimer epitope (21). 
3C-H5L1 may belong to the latter category.
While Barba-Spaeth et al. found that their cross-reactive fusion loop–binding mAbs had poor ZIKV neu-
tralizing capacity even at 1 μM (~150 μg/ml) (21), our fusion-loop binder 1B-H1L1 clearly decreased ZIKV 
infectivity at 2 μg/ml onwards. With an IC50 of  19.25 μg/ml, SIgN-3C is also considerably more potent at 
neutralizing ZIKV in vitro than the murine ZIKV/DENV fusion loop–targeting antibody 2A10G6, which 
had a 50% plaque reduction titer of  249 μg/ml (24). On the other hand, SIgN-3C is not as potent as antibod-
ies that were isolated from ZIKV-immunized mice (40) or ZIKV-infected patients (41–43), which had report-
ed IC50 values as low as 0.1 and 0.01 μg/ml, respectively. However, it is difficult to compare IC50 values 
obtained using different methodologies and virus strains, and ultimately, in vivo efficacy is more important. 
As demonstrated in our current animal study, SIgN-3C was effective in suppressing ZIKV viremia, thereby 
protecting mice from rapid weight loss and ZIKV-induced lethality seen in the untreated group at 7 to 8 dpi.
Arguably, the largest health threat posed by the ZIKV epidemic is the risk of  microcephaly and 
other fetal abnormalities in virus-infected pregnant women. Recent studies have shown that in mice 
Figure 3. Treatment with SIgN-3C and its LALA variant prevent ZIKV-induced mortality in IFNAR–/– mice. (A) Mortality, (B) weight change, and (C) 
viremia of Zika virus–infected (ZIKV-infected) type I interferon receptor–deficient (IFNAR–/–) mice receiving isotype (n = 10), SIgN-3C (n = 5), and SIgN-
3C-LALA (n = 10) antibodies. Mice were inoculated with 104 PFU ZIKV s.c. at the ventral side of the footpad and treatments were given on days 1, 4, and 8 
after infection. Mice were treated with 1 mg per dose of SIgN-3C and 0.5 mg per dose of SIgN-3C-LALA. Data shown are representative of 2 independent 
experiments. (D) Viral load in brain, spleen, liver, kidney, testes, and popliteal lymph node (pLN) of ZIKV-infected IFNAR–/– mice receiving isotype (n = 5), 
SIgN-3C (n = 5), and SIgN-3C-LALA (n = 4) antibodies at 6 days after infection. The mortality curve was analyzed using a log-rank (Mantel-Cox) test, while 
weight change, viremia, and viral load were analyzed using the Kruskal-Wallis test with Dunn’s multiple comparison. *P < 0.05; **P < 0.01; ***P < 0.001.
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lacking type I interferon signaling, ZIKV infection of  pregnant mice resulted in virus transmission 
across the placenta to the fetus, causing fetal growth restriction and brain damage (38, 39). Here, we 
provide a proof  of  principle in a similar pregnant mouse model that maternal administration of  SIgN-
3C or SIgN-3C-LALA can result in drastic reduction of  viral load in the placenta and developing fetus 
and thus improve fetal development. Taken together with the work of  Sapparapu et al. using a mAb 
isolated from a ZIKV patient (42), our work supports the possibility of  using neutralizing antibodies as 
prophylactic or therapeutic interventions for pregnant women in ZIKV-endemic areas.
Repurposing of currently available mAbs against different pathogens can not only shorten the development 
time of new therapeutics but also broaden the therapeutic spectrum of the same mAb. Similar strategies have 
been proposed from various studies (24, 44). However, further antibody engineering of SIgN-3C may be vital 
for improving the safety and efficacy of this potential ZIKV therapeutic. As this mAb was induced against 
DENV and not ZIKV, it is likely that its potency can be improved by antibody affinity maturation using a direct-
ed evolution approach towards better ZIKV virion recognition. ADE of ZIKV infection by DENV antibodies 
Figure 4. SIgN-3C and SIgN-3C-LALA treatments prevent ZIKV-induced congenital developmental deficiency in IFNAR–/– mice. (A) Representative 
images and (B) weight of fetuses isolated from mock-infected type I interferon receptor–deficient (IFNAR–/–) mice, Zika virus–infected (ZIKV-infected) 
isotype control, and ZIKV-infected mice with SIgN-3C or SIgN-3C-LALA treatments (all groups n ≥ 7). Each data point in dot plots was obtained from 1 
fetus. Weights of fetuses are expressed relative to the mean of fetal weights from mock-infected IFNAR–/– mice. Viral load in the (C) amniotic fluid and (D) 
organs of fetuses from ZIKV-infected IFNAR–/– pregnant mice receiving isotype, SIgN-3C, and SIgN-3C-LALA antibodies (all groups n ≥ 7). Each data point 
in dot plots was obtained from 1 fetus. Mice were inoculated with 107 PFU ZIKV i.v. on E10.5 and treatments were given on days 0, 1, and 3 after infection. 
Mice were given 0.5 mg of isotype or treatment antibody per dose. All animals were harvested at E16.5. All data were analyzed using the Kruskal-Wallis 
test with Dunn’s multiple comparison. *P < 0.05, ***P < 0.001.
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remains a significant concern (20, 22). In flaviviruses, ADE-mediated DENV infection has been suggested to 
cause severe clinical outcomes following secondary DENV infections (45, 46) due to the cross-reactivity between 
DENV-specific antibodies and different serotypes of DENV (33). Hypotheses have suggested that the occur-
rence of extrinsic and intrinsic ADE mechanisms (33) cause high circulating virus titers in patients that lead to 
severe clinical outcomes . For a therapeutic mAb, there is a risk of ADE when its serum concentration drops 
below its neutralizing threshold. Improving the human mAb affinity is likely to lower its neutralization threshold 
and thus reduce the risk of ADE. Engineering the Fc region of the human mAb to reduce Fc receptor binding 
has been shown to abrogate ADE by DENV antibodies (41, 47, 48). We show in this study that introducing the 
LALA mutation in SIgN-3C eliminated ZIKV ADE in vitro without compromising the neutralization capacity 
in vivo, presenting SIgN-3C-LALA as a viable alternative that sufficiently protects against ZIKV infection in 
vivo. On the other hand, a possible link between the Sanofi Dengvaxia vaccine and patients who displayed severe 
clinical outcomes could be coupled with the presence of cross-reactive antibodies that induce ADE, and also the 
lack of protective T cell immunity after vaccination (49). A recent study has indicated the importance of DENV 
NS1 protein–mediated T cell response in natural immunity or vaccination to confer protection against DENV 
infection (50). Therefore, we recommend that comprehensive protection from ZIKV infection might require the 
presence of antibodies (for example SIgN-3C-LALA) in the vaccine formulation and the eventual activation of  
T cell immunity through presentation of ZIKV NS1 protein.
Methods
Virus. The ZIKV Polynesian isolate was obtained from the European Virus Archive (EVA) and the ZIKV 
Brazilian isolate was obtained from the Centre for Virus Research, University of  Glasgow, Glasgow, UK. 
Viruses were propagated in Vero-E6 cells (ATCC, CRL-1587) or in C6/36 cells (ATCC, CRL-1660) and 
prepared for infection studies. Expanded virus stocks were purified via ultracentrifugation (51), and titered 
by standard plaque assay using Vero-E6 cells (52).
Expression and purification of  human DENV mAbs. Single plasmablasts were isolated from 2 DENV-in-
fected patients (1 DENV2- and 1 DENV3-infected patient) and human DENV mAbs were expressed and 
purified from HEK-293-6E cells as described previously (25, 26).
Virus-neutralization assay. Neutralizing activity of  human DENV mAbs was tested in triplicate and ana-
lyzed by immunofluorescence-based cell infection assay in Vero-E6 cells. ZIKV were mixed at MOI 10 with 
diluted (0.029–30 μg/ml) human mAb and incubated for 2 hours at 37°C with gentle agitation (350 rpm). 
Virus-mAb mixtures were then added to Vero-E6 cells seeded in 96-well plates and incubated for 2 hours at 
37°C. Medium was removed, and cells were replenished with DMEM (Hyclone) supplemented with 10% 
FBS (Hyclone) and incubated for 48 hours at 37°C before fixation with 4% paraformaldehyde (Electron 
Microscopy Sciences). Cells were permeabilized with PBS containing 0.2% Tween-20 and incubated for 
10 minutes at room temperature. Cells were stained with mouse anti-flavivirus antibody (Merck Millipore, 
clone D1-4G2-4.15) diluted in PBS for 1 hour at 37°C. This was followed by incubation with goat anti-
mouse secondary antibody conjugated to fluorescein isothiocyanate (FITC) (Life Technologies; catalog 
F-2761) for 1 hour at 37°C. Cell nuclei were labeled with DAPI. Images were acquired and analyzed quan-
titatively by the Cellomics ArrayScan VTI HCS Reader. IC50 was calculated with Prism software (Graph-
Pad Software, Inc.), applying a 3-parameter nonlinear regression curve fit.
Human mAb reactivity with ZIKV determinants. First, a ZIKV virion-based ELISA assay was performed as 
described previously (51). Virion-reactive human mAbs were then tested for their capacity to react with ZIKV 
single antigens expressed on the surface of transfected K562 cells. Using a synthetic codon-optimized sequence 
based on the published Suriname isolate (KU312312, see ref. 7), the ectodomain of ZIKV E (with the trans-
membrane region deleted) was cloned into the pDisplay vector (Life Technologies), which fuses the protein to an 
N-terminal signal peptide and a C-terminal platelet-derived growth factor receptor transmembrane anchor. The 
complete open reading frame was then subcloned into the lentiviral transfer vector pWPXL (provided by Didier 
Trono, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland). Lentiviral particles were generated 
as previously described (53) and used to transduce K562 cells, which were then sorted based on expression of  
the HA epitope tag. Similar K562 cell lines surface-displaying ZIKV prM and NS1 were generated using len-
tivector constructs bearing full-length synthetic genes. Surface expression of the ZIKV E ectodomain was greatly 
enhanced by incubating the cells at 32°C for 24 hours. Each cell line was then incubated with 1 or 10 μg/ml of  
human DENV mAb for 30 minutes at room temperature prior to labeling with an Alexa Fluor 647 goat anti-hu-
man secondary antibody (ThermoFisher Scientific; catalog A-21445) for analysis by flow cytometry.
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Peptide-based ELISA. Epitope screening was performed on synthesized biotinylated peptides (Mimotopes) 
consisting of  18-mer overlapping peptides generated from ZIKV Polynesian isolate (KJ776791) and the con-
sensus sequence of  DENV3 strains (KR296743, KF973487, EU081181, KF041254, JF808120, JF808121, 
KJ189293, KC762692, KC425219, KJ830751, KF973479, and AY099336) as previously described (51).
Protein structures. Structure of  the dengue serotype 3 and Zika E proteins were retrieved from the PDB 
(54). The dengue serotype 3 E structure was derived from the cryo-EM structure PDB 3J6U (29) and the 
full atomic representation was reconstructed using Yasara (55). The Zika E structure is derived from PDB 
5IZ7 (30). All structures were visualized using PyMOL.
ZIKV-ADE assay. ZIKV (MOI 10) was first incubated with diluted human DENV mAbs in serum-free 
IMDM (Gibco) for 2 hours on a shaking heat block (37°C, 350 rpm) before being used to infect the K562 
cells for 1.5 hours in a 37°C incubator, supplemented with 5% CO2. The virus overlay was removed and 
cells were washed once before they were resuspended in appropriate complete medium. Cells were further 
incubated at 37°C, supplemented with 5% CO2. Seventy-two hours after infection, 140 μl of  infected cell 
suspension was aliquoted for vRNA extraction. Mock and nonenhanced control infections were performed 
by incubating cells with serum-free IMDM and viruses, respectively. Results are expressed as fold increase 
of  ZIKV viral load relative to nonenhanced infections.
Mouse protection experiments. For the nonpregnant ZIKV mouse model, 4-week-old IFNAR–/– mice in the 
C57BL/6J background were used. Animals were inoculated s.c. in the ventral side of  the right footpad with 
104 PFU ZIKV propagated in C6/36 cells (30). Mice were subsequently given 500 μg to 1 mg of  human 
DENV mAb SIgN-3C or SIgN-3C-LALA via i.p. injection on 1, 4, and 8 dpi. A human chimeric IgG1 
isotype control with an unrelated specificity was included as isotype control group. Mortality, weight loss, 
disease signs, viremia, and viral load in major organs were monitored.
For the pregnant ZIKV mouse model, 8- to 10-week-old female IFNAR–/– mice were used for time 
mating and infection. Particularly, mating pairs housed in the same cage were separated in the morn-
ing and embryonic development was estimated by considering the day of  vaginal plug observation as 
0.5 days after conception. Pregnant mice were inoculated intravenously (i.v.) with 107 PFU ZIKV on 
day 10.5 after conception. Mice were subsequently given 500 μg of  SIgN-3C-LALA or isotype control 
mAb via i.p. injection on 0, 1, and 3 dpi. On day 16.5 after conception, pregnant mice were sacrificed 
and fetuses were harvested. Fetus weights were taken and viral load in the amniotic fluid, placenta, 
fetal brain, and fetal liver were quantified.
Viral load quantification. For viremia quantification, 10 μl of  blood collected from the tail vein was 
diluted in 120 μl PBS and 10 μl citrate-phosphate-dextrose solution (Sigma-Aldrich). vRNA was extracted 
with a QIAmp Viral RNA kit (QIAGEN) in accordance with the manufacturer’s protocol. For viral load 
quantification in amniotic fluid, total amniotic fluid was collected from each conceptus sac after disrup-
tion of  the surrounding membrane. vRNA was extracted with a QIAmp Viral RNA kit. For all other solid 
tissues, samples were placed in 2-ml microtubes (Labcon) containing 500 μl to 1 ml of  TRIzol (Invitrogen) 
and 2-mm disruption beads (Tomy, model ZB-20). Tissues were homogenized twice in a bead-based cell 
disrupter (Micro Smash MS-100) at 5,000 rpm for 45 seconds each. Total RNA was then extracted into the 
aqueous phase using a TRIzol-chloroform method as previously described (56), followed by purification 
using an RNeasy kit (QIAGEN) following the manufacturer’s protocol. NS5 RNA copies were quantified 
in 1 μl of  total RNA or vRNA by quantitative reverse transcription PCR (qRT-PCR) using the QuantiTect 
Probe RT-PCR Kit (QIAGEN) adapted from a previously reported protocol (57).
Statistics. All data were analyzed using Prism software. For virus-neutralization assays, the data were 
curve-fit by 3-parameter nonlinear regression analysis, after which the mAb dose that resulted in 50% neu-
tralization was calculated (IC50). For all data presented in the animal studies, Kruskal-Wallis with Dunn’s 
multiple comparisons were done for datasets with 3 groups and above, while Mann-Whitney 2-tailed anal-
ysis was done for datasets with 2 groups. All in vitro data are presented as mean ± standard deviation (SD) 
or standard error of  the mean (SEM); in vivo data are presented as mean (1 dot per sample). P values less 
than 0.05 were considered statistically significant.
Study approval. All mouse studies were approved by the IACUC (approval 151038) of  the Singapore 
A*STAR, performed according to the guidelines of  the Agri-Food and Veterinary Authority and the 
National Advisory Committee for Laboratory Animal Research of  Singapore. All animals used were bred 
under specific pathogen–free conditions in the Biological Resource Centre (A*STAR).
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